- In April 2023, Cytiva, a global provider of life sciences technologies, expanded its VIA Thaw platform by launching a new GMP-compliant model designed for commercial cell therapy production. This new version features enhanced automation, real-time temperature monitoring, and integrated data logging capabilities to meet the rigorous requirements of large-scale manufacturing. The development reinforces Cytiva’s commitment to supporting the scalability and standardization of advanced therapy workflows through innovative thawing solutions
- In March 2023, BioLife Solutions, Inc. introduced an upgraded version of its evo® Smart Thawing System, equipped with wireless connectivity and improved user interface features. The system now allows for remote monitoring and traceability, ensuring better quality control and compliance in the thawing of cryopreserved cell therapies. This advancement highlights BioLife’s continued leadership in cryopreservation and thawing technologies that support the safe, efficient delivery of cell-based therapies to patients
- In February 2023, Sartorius AG announced a collaboration with a leading European biopharmaceutical company to co-develop a fully closed, automated thawing solution tailored for stem cell-derived therapies. The partnership aims to accelerate clinical translation and streamline manufacturing workflows by minimizing contamination risk and improving thaw consistency. This initiative demonstrates Sartorius’ strategic focus on innovation and customized solutions for cell and gene therapy manufacturing
- In January 2023, Thermo Fisher Scientific Inc. launched its CryoMed Controlled-Rate Thawing System for clinical research and biopharma applications. The system is designed to ensure consistent thawing of critical biological samples with high reproducibility, supporting regulatory compliance and improving workflow efficiency. The launch marks Thermo Fisher’s expanded commitment to providing advanced tools for end-to-end cell therapy processing
- In January 2023, Vineti, a digital supply chain platform for cell and gene therapies, integrated thawing data capture functionality into its personalized therapy management system. This update enables real-time documentation of thawing events, enhancing traceability and improving chain-of-identity and chain-of-condition compliance. The integration reflects the growing importance of digitalization in ensuring product quality and regulatory readiness throughout the cell and gene therapy lifecycle
